UTHR CFO exercises options and sells 10,000 shares
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sale transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sale transaction in company stock. He exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and, on the same date, sold 10,000 shares in multiple open-market trades at weighted average prices generally between about $568 and $579 per share. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, he directly holds 18,876 shares of Common Stock.
Insights
CFO exercised 10,000 options and sold 10,000 shares under a pre-planned Rule 10b5-1 plan.
CFO and Treasurer James Edgemond exercised stock options covering 10,000 shares of UNITED THERAPEUTICS Common Stock at an exercise price of $135.42 per share. On the same date, he executed open-market sales totaling 10,000 shares across multiple trades, with reported weighted average prices around $572–$579 per share.
The filing identifies these as open-market sales (code S) and an option exercise (code M), a classic exercise-and-sell pattern that converts an option position into cash. A key detail is that the activity occurred pursuant to a Rule 10b5-1 trading plan entered on October 31, 2025, indicating the trades were pre-scheduled rather than discretionary.
After the transactions, Edgemond directly owns 18,876 shares of Common Stock, so he retains a meaningful equity stake. The derivativeSummary is empty, showing no remaining options from this particular grant. Overall, this appears as routine, pre-planned liquidity rather than an abrupt change in exposure, and on its own does not clearly alter the company’s investment profile.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 80 | $568.7394 | $45K |
| Sale | Common Stock | 80 | $570.5188 | $46K |
| Sale | Common Stock | 603 | $571.5252 | $345K |
| Sale | Common Stock | 970 | $572.7823 | $556K |
| Sale | Common Stock | 2,456 | $574.036 | $1.41M |
| Sale | Common Stock | 3,419 | $574.7609 | $1.97M |
| Sale | Common Stock | 1,712 | $575.7814 | $986K |
| Sale | Common Stock | 293 | $576.7505 | $169K |
| Sale | Common Stock | 307 | $577.9287 | $177K |
| Sale | Common Stock | 80 | $578.585 | $46K |
Footnotes (11)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F10. This transaction was executed in multiple trades at prices ranging from $577.41 to $578.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $578.49 to $578.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $568.685 to $569.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $570.01 to $570.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $571.17 to $572.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $572.21 to $573.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $573.33 to $574.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $574.33 to $575.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $575.33 to $576.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $576.41 to $577.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
stock options financial
weighted average price financial
open-market sale financial
derivative security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did UNITED THERAPEUTICS (UTHR) CFO James Edgemond report in this Form 4?
What stock options did the UNITED THERAPEUTICS (UTHR) CFO exercise in this filing?
Does this UNITED THERAPEUTICS (UTHR) Form 4 indicate a change in derivative positions?
AI-generated analysis. How Rhea-AI works. Not financial advice.